Washington [US], July 28 (ANI): A new class of glioma medications takes advantage of tumours lacking the DNA repair enzyme MGMT; the medications cause the generation of cytotoxic DNA and kill tumour cells specifically without the risk of developing resistance, according to research.
New Haven [US], June 6 (ANI): Patients with advanced pancreatic neuroendocrine tumours (NETs) have few treatment options, but researchers at Yale Cancer Center and Yale-New Haven Health's Smilow Cancer Hospital discovered that patients who received a combination of capecitabine and temozolomide had a higher progression-free survival rate than those who received temozolomide alone.
Washington [US], October 6 (ANI): Researchers at MIT and Dana-Farber Cancer Institute have developed a new way to determine whether individual patients will respond to a specific cancer drug or not. This kind of test could help doctors to choose alternative therapies for patients who don't respond to the therapies normally used to treat their cancer.
\
\
\
\
\
\
